first_imgJohn Trifone joins Blue Cross and Blue Shield of Vermonts Management TeamBerlin, VT John Trifone, of Montpelier, VT, has been named Vice President, Treasurer & Chief Financial Officer at Blue Cross and Blue Shield of Vermont (BCBSVT).Mr. Trifone has expertise and experience in finance, treasury and information technology functions, as well as management and process improvement. He will be accountable for Corporate Accounting, Treasury, Actuarial, Underwriting, Legal and Facilities functions at the states largest health insurer.Prior to joining BCBSVT, Mr. Trifone was employed at Blue Cross and Blue Shield of Mississippi where he served both as Vice President for Finance, and Corporate Vice President for Information Technology & Development. Previously, he served as Chief Financial Officer at Laureate Psychiatric Clinic & Hospital, and spent fourteen years in “Big 4” public accounting in both auditing and management consulting positions. He is a CPA in the States of Mississippi and Connecticut.Blue Cross and Blue Shield of Vermont is the state’s oldest and largest private health insurer, providing coverage for about 180,000 Vermonters. It employs over 350 Vermonters at its headquarters in Berlin and branch office in Williston, and offers group and individual health plans to Vermonters. More information about Blue Cross and Blue Shield of Vermont is available on the Internet at www.bcbsvt.com(link is external). Blue Cross and Blue Shield of Vermont is an independent corporation operating under a license with the Blue Cross and Blue Shield Association, an association of independent Blue Cross and Blue Shield Plans.(End)last_img read more

first_img Qualifying ends for fall judicial races There are 26 circuit court races — or more than one out of every 10 circuit judgeships up for election this year — that drew contested races as of the close of filing May 17. In addition, 24 district court of appeal judges, as well as outgoing Supreme Court Chief Justice Charles Wells and incoming Chief Justice Harry Lee Anstead, have filed for merit retention.Another nine circuit court seats, just created by the legislature, will be open for qualifications in July. Traditionally, open seats are much more likely to attract contested races than those occupied by incumbents.Contested races will be on the September primary ballot, with any resulting runoffs decided on the November general election ballot. The merit retention votes will be on the November ballot.One result of interest to the Bar is Board of Governors member John Marshall Kest was elected without opposition to a Ninth Circuit judgeship. (Data for county judge races is not collected statewide, but is available county by county from local elections supervisors.)Contested races are:In the Fourth Circuit, John Joseph Cascone and W. Gregg McCaulie for Group 5 and David M. Gooding and Dan Wilensky in Group 13.In the Fifth Circuit, Carven D. Angel and Michael G. Takac in Group 1.In the Sixth Circuit, Wayne L. Cobb and Chris Yeazell in Group 8, Declan Mansfield and John Renke in Group 25, Linda Babb, George H. Brown, and Sarah Chaves for Group 26, and Robert “Bo” Michael and Jack R. St. Arnold for Group 28.In the Seventh Circuit, Jim Clayton and Terry LaRue for Group 7.In the Ninth Circuit, Alan Apte, Ted Marrero, and Neal P. Pitts in Group 21.In the 11th Circuit, Ivan Fernandez and Alan I. Mishael in Group 1, Mary Barzee and Yolly Roberson in Group 2, Alan L. Postman and Diane Ward in Group 4, and Alexander O. Akpodiete, Xavier Cortada, Raul G. Ordonez, Jr., and Sarah Zabel in Group 46.In the 12th Circuit, Susan Chapman, Charlie Roberts, Adam Tebrugge and Laurie Zimmerman for Group 5.In the 13th Circuit, Kevin Carey and Walter Foster in Group 7, William P. Levens and Brent Warren Yessin in Group 28 and Martha Cook, Carlos A. Pazos, and Ken Whalen in Group 30.In the 15th Circuit, Bill Berger and Bennett S. Cohn in Group 3, Martin H. Colin and Diana Lewis in Group 14, and Scott S. Britan and Jeffrey A. Winikoff in Group 31.In the 17th Circuit, Michael J. Orlando and Mila K. Schwartzreich in Group 11, John Bowman, Mariza de Guzman Cobb, and Alan Marks in Group 26, David Krathen and Nicholas “Nick” Lopane in Group 29, Hope Tieman Bristol and Andrew “Andy” Siegel in Group 37, and Michael E. Gilfarb, Ronald M. “Ron” Gunzburger, Joyce Anne Maines-Julian, and John J. Murphy III for Group 41.In the 19th Circuit, Roy T. Mildner and Larry Schack in Group 11. Appellate Courts Filing to run for merit retention, besides Anstead and Wells on the Supreme Court, were:On the First District Court of Appeal, Judges Robert T. Benton, Marguerite H. Davis, Joseph Lewis, Jr., Ricky L. Polston, and William A. Van Nortwick, Jr.On the Second District Court of Appeal, Judges Chris W. Altenbernd, Virginia Covington, Carolyn K. Fulmer, Jerry R. Parker, Morris Silberman, and James W. Whatley.On the Third District Court of Appeal, Judges Gerald B. Cope, Jr., David M. Gersten, Melvia B. Green, David L. Levy, and Juan Ramirez, Jr.On the Fourth District Court of Appeal, Judges Mark E. Polen, George A. Shahood, W. Mathew Stevenson, and Martha C. Warner.On the Fifth District Court of Appeal, Judges Richard B. Orfinger, William David Palmer, Robert J. “Bob” Pleus, Jr., and Thomas D. Sawaya. Uncontested Circuit Following are circuit judge candidates who were elected or reelected without opposition. Most are incumbents, but state elections information does not denote a difference between incumbents and nonincumbents:In the First Circuit, G. Robert Barron, T. Michael “Mike” Jones, Kim A. Skievaski, Nickolas P. Geeker, Paul A. Rasmussen, John T. Parnham, Jan Shackelford, Edward P. Nickinson III, Kenneth L. Williams, Ken Bell, and Mike Allen.In the Second Circuit, Kathleen F. Dekker, P. Kevin Davey, William L. Gary, N. Sanders Sauls, Tom Bateman, John C. Cooper, John E. Crusoe, and Charles A. Francis.In the Third Circuit John Weston Peach and Julian E. Collins.In the Fourth Circuit, Jean Johnson, Frederic A. Butner, Lance M. Day, Charles O. Mitchell, Jr., Donald R. Moran, Jr., Peter J. Fryefield, Aaron K. Bowden, John H. Skinner, Brad Stetson, Bernard Nachman, and Waddell A. Wallace III.In the Fifth Circuit, Barbara Gurrola, Richard “Dick” Tombrink, Jr., Mark J. Hill, William Jack Singbush, Richard A. Howard, Don F. Briggs, Jack Springstead, G. Richard Singeltary, Sandra Edwards-Stephens, T. Michael Johnson, Brian D. Lambert, and Curtis J. Neal.In the Sixth Circuit, Lauren C. Laughlin, Raymond O. Gross, W. Lowell Bray, Jr., Marion L. Fleming, James R. Case, Walt Logan, Mark Shames, Stanley R. Mills, Anthony Rondolino, Bruce Boyer, Tim Peters, John A. Schaefer, and Daniel D. Diskey.In the Seventh Circuit, J. David Walsh, Edward E. Hedstrom, R. Michael Hutcheson, John V. Doyle, Edwin P.B. Sanders, John M. Alexander, Julianne Piggotte, Shawn L. Briese, Robert K. Mathis, Robert K. Rouse, Jr., and Hubert L. Grimes.In the Eighth Circuit, Frederick D. Smith, Martha Ann Lott, and Peter K. Sieg.In the Ninth Circuit, John Kest, James C. Hauser, William C. Gridley, Maura T. Smith, Walter Komanski, John H. Adams, Sr., Roger J. McDonald, George Sprinkel, Dorothy J. Russell, Daniel Dawson, Anthony “Tony” Johnson, A. Thomas Mihok, Reginald Karl Whitehead, Donald E. Grincewicz, Frederick J. Lauten, and Janet C. Thorpe.In the 10th Circuit, Roger A. Alcott, Julian Dale Durrance, David Langford, Dennis P. Maloney, Susan W. Roberts, J. Michael McCarthy, Dick Prince, Wm. Bruce Smith, and Charles Lee Brown.In the 11th Circuit, Amy Steele Donner, Margarita Esquiroz, Jose M. Rodriguez, Ronald M. Friedman, Eugene J. Fierro, Leon Firtel, Daryl E. Trawick, Jon I. Gordon, Manny Crespo, Peter Lopez, Ronald Dresnick, Joseph P. Farina, Roberto M. Pineiro, Celeste Hardee Muir, Leonard E. Glick, Jerald Bagley, Stuart M. Simons, Kevin Emas, Thomas S. Wilson, Jr., Jeri Beth Cohen, Bernard S. Shapiro, Marc Schumacher, Jeffrey Rosinek, Jacqueline Hogan Scola, Cecilia M. Altonaga, Robert N. Scola, Jr., Sandy Karlan, and Victoria Sigler.In the 12th Circuit, Durand J. Adams, Rick De Furia, Andrew D. Owens, Bob McDonald, Peter A. Dubensky, Marc B. Gilner, and Deno Economou.In the 13th Circuit, Frank A. Gomez, Barbara Fleischer, Marva L. Crenshaw, Dan Perry, James D. Arnold, Gregory P. Holder, Rex Martin Barbas, Ralph C. Stoddard, Charlene E. Honeywell, Jack Espinosa, Jr., Robert J. Simms, Claudia Isom, Chet A. Tharpe, Manuel Menendez, Jr., Sam Pendino, J. Rogers Padgett, Vivian C. Maye, Wayne S. Timmerman, Richard A. Nielsen, Katherine G. Essrig, James M. Barton II, and Herbert J. Baumann, Jr.In the 14th Circuit, William L. Wright, Judy Pittman, Hentz M. McClellan, and Michael C. Overstreet.In the 15th Circuit, Elizabeth T. Maass, Mary E. Lupo, Jorge Labarga, John J. Hoy, Tom Barkdull, Jeffrey J. Colbath, Richard I. Wennet, Gary L. Vonhof, John L. Phillips, Lucy Chernow Brown, and Sandra K. McSorley.In the 16th Circuit, Mark Jones, Luis M. Garcia, and Sandra Taylor.In the 17th Circuit, James I. Cohn, John A. Frusciante, Barry E. Goldstein, Larry Seidlin, Melvin B. “Mel” Grossman, Jeffrey E. Streitfeld, Patti Englander Henning, Victor “Vic” Tobin, Stanton S. Kaplan, Lawrence L. “Larry” Korda, Tom Lynch, Leroy H. Moe, George Angen Brescher, Charles Michael Greene, Renee Goldenberg, Marc H. Gold, Dorian K. Damoorgian, Susan J. Aramony, and Alfred J. Horowitz.In the 18th Circuit, Preston Silvernail, Nancy Alley, Donna McIntosh, Bruce W. Jacobus, John Dean Moxley, Jr., John M. “Jack” Griesbaum, Tonya Rainwater, James E.C. Perry, Meryl L. Allawas, Charles M. Holcomb, Alan A. Dickey, Kenneth R. Lester, Jr., and Vincent George Torpy, Jr.In the 19th Circuit, Ben L. Bryan, Jr., Steven J. Levin, Robert R. Makemson, Cynthia L. Cox, Bill Roby, and Dan L. Vaughn.In the 20th Circuit, Lynn Gerald, Jr., Ted Brousseau, Daniel R. Monaco, Hugh D. Hayes, William C. McIver, Hugh E. Starnes, Donald E. Peliecchia, Isaac Anderson, Jr., Sherra Winesett, John S. Carlin, and G. Keith Cary. Qualifying ends for fall judicial racescenter_img June 1, 2002 Regular Newslast_img read more

first_imgSign up for our COVID-19 newsletter to stay up-to-date on the latest coronavirus news throughout New York Thousands of firefighters lined the streets of Bethpage on a misty Thursday morning to pay tribute to FDNY veteran William Tolley, who plunged to his death last week battling a fire in Queens.Fellow firefighters had flooded Tolley’s hometown for a series of memorial services this week and their numbers grew exponentially Thursday as more than 10,000 people were expected to attend the funeral service. Outside the church, red ribbons abutted utility poles and American flags hung high.The steady mist eventually gave way to cloudy skies, punctuating the occasion as a somber mood enveloped the area around St. Martin of Tours church. With police enforcing morning road closures, the long stretch running from Hicksville Road to Bethpage State Parkway was eerily quiet until mourners trickled in for the ceremony.“His life was so rich, so rich in fact, that it makes the loss even more raw and painful,” New York City Mayor Bill DeBlasio told mourners. “But let’s take stock and remember a rich life and a full life…a life lived the way we all should live.”Tolley, 42, and about 100 other firefighters were battling a blaze at a five-story building in Ridgewood, Queens last Thursday when he fell to his death. The circumstances around his fatal fall are currently under investigation.The funeral marked a tragic end to a life of a man whose love for his family, his wife Marie and 8-year-old daughter Bella, was endless.“Bella was his first and foremost priority, the apple of his eye,” Tolley’s colleague Jarrett Kotarski said while also recalling Tolley playing drums in the heavy metal band Internal Bleeding. “Billy lived his life to the fullest, he chased down all his dreams and caught them.”Leading the procession was Tolley’s Ladder Company 135, including one in black and purple bunting carrying his American flag-draped casket. Tolley’s widow and daughter followed the casket into the church as hymns blared.The words “In Loving Memory of William N. Tolley” word etched into the truck.“His death leaves so much pain, confusion and crying,” said Father Patrick Woods, recalling the moment of devastating grief when Tolley’s daughter, Bella, learned of her father’s death.“Mommy, why are you gone all day, what happened?” she asked.“Marie a loving mother carrying her own crushing grief, gently tells Bella that Billy has gone home to God,” he recalled.“Mommy,” Bella responded, “daddy is too young to die.”And then she realized.“I have no daddy.”Consoling Bella, Marie reminded her that Tolley loved helping people.“That’s what firemen do,” she said.William Tolleylast_img read more

first_imgIn addition to this, the following statement by State Senator Fred Akshar was sent to 12 News: The Southern Tier is expected to move onto the fourth phase on Friday. In a statement sent to 12 News, Assemblywoman Donna Lupardo said the following: I can see why businesses, and some non-profits like the YMCA, are frustrated by this unexpected news. They had reworked their operations in order to comply with new health and safety guidance. New Yorkers have successfully reduced spread of COVID by respecting the health of our fellow community members. I think we are ready to responsibly take on this next set of openings, knowing that if our COVID numbers begin it rise, actions can be taken. Broome County Executive Jason Garnar says the state must allow all businesses to reopen in the final phase for the economy to fully return. (WBNG) — Local officials are reacting to the news that malls, gyms and theaters will not be opening as part of Governor Andrew Cuomo’s reopening plan. In the dark of the night, the state cancelled these plans, and instead declared that motion picture, TV and streaming service production, as well as ‘low-risk’ indoor and outdoor arts and entertainment could resume operations. No date or plan has been given for movie theaters or gyms, only the pithy promise of “soon.” It’s just another example of arbitrary, confusing and contradictory messages coming from Albany bureaucrats.last_img read more

first_img To achieve prepandemic vaccines, researchers would have to ascertain the right dose and dose interval, determine how long priming lasts, and solve the puzzle of measuring primed immunity. Further, regulatory authorities would have to determine the trial design that could deliver those answers, the public discussion that would be necessary for prepandemic vaccines to be accepted, and the safety data that would need to be gathered once the vaccines went into use (see Bibliography: Goodman 2007). A number of the studies that have shown adjuvants may be able to stretch the vaccine supply also demonstrated a secondary benefit: The formulas protected not only against the H5N1 flu strain on which they were based, but against other H5N1 strains as well, a phenomenon called cross-reactive protection (see Bibliography: Nicholson 2001, Stephenson 2005, Govorkova 2006, Hehme 2007, Hoffenbach 2007). Most recently, the GlaxoSmithKline-backed team that described an acceptable immune response after two adjuvanted 3.8-microgram (mcg) doses found that three fourths of their subjects were protected not only against the clade 1 Vietnam virus on which the vaccine was based, but against a drifted clade 2 virus from Indonesia as well (see Bibliography: Leroux-Roels 2007). “I think priming should be done, but I am not sure how it should be done,” said Dr. John Wood, principal scientist in the division of virology at the United Kingdom’s National Institute for Biological Standards and Control. “What we don’t know is how low you can go to actually prime people. It may be that you can go much lower than where we can detect antibody. That is a regulatory headache, because you have to demonstrate that you are doing something, but there is a potential there” (see Bibliography: Wood 2007: author interview). At the moment, however, the science is thin. Much of the support for priming has come from animal studies (see Bibliography: Lipatov 2005, Govorkova 2006, Kreijtz 2007) or via computer modeling (see Bibliography: Longini 2005, Ferguson 2006, Germann 2006). A few small studies in humans have shown promising results. In one, serum from 15 volunteers who received three doses over 16 months of an adjuvanted vaccine based on a 1997 H5N3 isolate showed significant antibody response against H5N1 strains isolated years later (see Bibliography: Stephenson 2005). In another, 37 participants who had been given a baculovirus-grown, clade 3 H5 vaccine in 1998 were boosted with a single dose of the unadjuvanted 90-mcg Sanofi vaccine in 2005, and showed much higher antibody responses than participants who had not been primed but received one or two doses of the 90-mcg vaccine (see Bibliography: Treanor 2007: Immune responses). And researchers at a conference earlier this year reported that some of the participants in the phase 3 trial of the 90-mcg Sanofi vaccine were boosted with a third dose 6 months after their second dose and showed a significant rise in antibody levels that lasted for 6 months (see Bibliography: Zangwill 2007). A tough ethical problemBut the next logical step—that if vaccines can be formulated without waiting for a pandemic, they could be administered before a pandemic began—is a much tougher one to take, and policy makers are approaching it with great caution. The scientific, logistical, and especially ethical questions raised by prepandemic vaccination are grave. “Extraordinary threats call for consideration of innovative strategies that, in less-threatening circumstances, might be dismissed,” Bruce Gellin and Ben Schwartz of the Department of Health and Human Services’ National Vaccine Program Office wrote 2 years ago. “Although it has been assumed that pandemic vaccine cannot be stockpiled or that vaccination cannot occur before the start of a pandemic, might these approaches actually be possible? . . . Would receipt of a vaccine prepared before the pandemic be effective in providing some protection or in priming recipients so a single subsequent dose of vaccine would be protective?” (see Bibliography: Schwartz 2005). The danger demonstrated by both those campaigns, of causing adverse events while protecting against a disease that might never arise, has been noted in World Health Organization (WHO) policies as well. “Possible high-risk shortcuts in response to a potential emergency would be difficult to justify prior to the actual occurrence of the emergency,” the agency said after the June 2006 meeting of its Global Advisory Committee on Vaccine Safety. “Effectiveness of pandemic vaccines will not be known before the pandemic and possibly only after it is over” (see Bibliography: WHO 2006: Global Advisory Committee on Vaccine Safety, 6-7 June 2006). The prime-boost strategyThe most likely and biologically plausible use of prepandemic vaccination would be as the first half of a “prime-boost” series. People would still be given the two doses of vaccine necessary to provoke immunity in a naïve individual. But the doses would be based on different vaccine strains—the first an early best guess, the second tuned to the pandemic strain—and could be given not weeks but months or years apart if the science supported it. Yet the potential benefits of prepandemic vaccination are so alluring that governments have begun gingerly to lay groundwork for its consideration, despite the obvious difficulties of putting the idea into practice. The findings are not completely understood, though researchers agree that they make biological sense. Adjuvants stimulate the immune system in some manner that is broader than and different from the body’s reaction to the antigen packaged with them. The discovery that adjuvanted flu vaccines may invoke cross-reactivity has generated tremendous excitement—because that could allow production of at least partially protective vaccines well in advance of a pandemic’s beginning. Part 1: Flu research: a legacy of neglectPart 2: Vaccine production capacity falls far shortPart 3: H5N1 poses major immunologic challengesPart 4: The promise and problems of adjuvantsPart 5: What role for prepandemic vaccination?Part 6: Looking to novel vaccine technologiesPart 7: Time for a vaccine ‘Manhattan Project’?Bibliography Hurdles are manySo many steps separate those early results from an agreed-upon policy that would allow for prepandemic vaccines—in an annual flu shot or stockpiled until the WHO declares a pandemic imminent—that it is unrealistic to expect them to be created any time soon. The scientific questions alone are significant and novel. Any vaccination that took place before a pandemic was detected would offer uncertain amounts of both benefit and risk. The vaccine might be cross-protective against a future pandemic—but the lag time to the pandemic’s emergence might be so long that the vaccination would seem pointless. As well, the vaccine might cause a greater-than-expected rate of adverse events, causing both direct harm to recipients and indirect damage to government credibility—results that would be particularly difficult to tolerate if vaccination proved unnecessary because the pandemic did not arrive. Those risks are not theoretical: They have been demonstrated in the United States twice in recent history, in the abortive 2002 smallpox vaccination campaign and the 1976 swine-flu campaign (see Bibliography: Kotalik 2005), which has haunted US flu decision-making ever since. Editor’s note: This is the fifth in a seven-part series investigating the prospects for development of vaccines to head off the threat of an influenza pandemic posed by the H5N1 avian influenza virus. The series puts promising advances in vaccine technology in perspective by illuminating the formidable barriers to producing large amounts of an effective and widely usable vaccine in a short time frame. Part 4 examined the possibility of using adjuvants to stretch the supply of pandemic vaccines and the regulatory barriers to that strategy. Recognizing those hurdles, the European Centre for Disease Prevention and Control said in August that while it welcomes the development of prepandemic vaccines, it would not support administering them until a WHO declaration of pandemic phase 5 or 6, meaning significant human-to-human transmission is occurring or a pandemic is under way (see Bibliography: ECDC 2007: “Pre-pandemic” vaccines might offer protection but uncertainties remain). The pandemic vaccine puzzle Oct 31, 2007 (CIDRAP News) – Experiments with vaccine adjuvants have raised some hope of removing one of the great stumbling blocks to pandemic influenza preparedness: the impossibility of making a vaccine that protects against a pandemic virus before that virus actually emerges. last_img read more

first_img“It’s their form of solidarity and support for fellow Chinese who are currently enduring a rough time because of the outbreak,” he added.Suwarso said the tourists made up the third and final batch of Chinese tourists departing from Batam after their travel agents had shortened their holiday period in Indonesia due to the recent upsurge of confirmed cases of the coronavirus in China. The first outflow of Chinese tourists from Batam occurred Monday with 145 tourists returning home that day, followed by 127 tourists the next day.“In total, our figures show that 399 Chinese tourists have returned to China this week alone,” Suwarso said.Suwarso also said the airport terminated on Tuesday two direct flights to and from two cities in China — Shenzhen and Xian — even though the flights were recently added to the airport’s newest flight schedule. He said the direct flight connecting Batam and Shenzhen launched on Dec. 28 while the flight between Batam and Xian opened on Jan. 1.“We finally terminated both flights after many requests from travel agents in China,” Suwarso said.Meanwhile, the head of the Batam chapter of the Association of Indonesian Tour and Travel Agencies (ASITA), Andika Lim, said the coronavirus outbreak in China would hit the tourism sector in Batam since the majority of international tourists there came from China.“So far, we are still calculating the losses in the tourism sector as the coronavirus outbreak has caused a major drop in the number of Chinese tourists visiting Indonesia,” Andika said. (glh)Topics : More than 100 Chinese tourists shouted “Jia you, Wuhan!” (Stay strong, Wuhan!) in unison while standing in line at Hang Nadim International Airport in Batam, Riau Islands, to depart for their home in Shenzhen, China, on Thursday afternoon.“They shouted those words as a form of encouragement for the city of Wuhan, which is currently in the spotlight for being the origin of the coronavirus outbreak,” Suwarso, the head of the airport, told The Jakarta Post on Friday.Beyond just shouting some words of encouragement, the tourists were also carrying 30 boxes of masks, each containing 50 facemasks, bought from pharmacies and drugstores all over Batam. They are to be given to Wuhan citizens after their arrival in China. The airport’s authority, he said, had granted the tourists authorization to carry the masks without further inspection of the items.last_img read more

first_imgIndoor dining in cafes and restaurants will resume on Friday, he said, with social distancing of 1.5 meters between groups.Marriages and funerals will also be allowed if the attendees wore face masks and kept two meters distance from each other.Bettel however said cafes and restaurants would have to close at midnight.Francois Koepp, the general secretary of the Horeca federation grouping hotels, restaurants and cafes, welcomed the announcement, saying the sector had “greatly suffered from the confinement”. Topics : He said it provided employment to some 21,000 people in this nation of 620,000 inhabitants.Cinema theatres and gyms will open at the end of the week but children’s parks will remain closed.The government has pledged to give every citizen over 16 a voucher worth 50 euros ($54) to spend in hotels to provide a boost to the sector.The vouchers will also be given to some 200,000 cross border workers from Belgium, France and Germany.center_img Luxembourg will ease its coronavirus restrictions on Wednesday, reopening cafes and restaurants and allowing civil and religious ceremonies under strict conditions, the government announced.The tiny country has so far registered only 3,993 COVID-19 cases, of which 110 have been fatal. Four people are in intensive care and shops were closed on March 18 to slow the spread of the new coronavirus.Prime Minister Xavier Bettel told a news conference on Monday that eateries could reopen terraces with a maximum of four people at a single table.last_img read more

first_imgTopics : At the same time Bayer announced it had also agreed separate multi-million-dollar payouts to resolve longstanding legal issues involving other Bayer products, as the group tries to turn the page on its courtroom dramas.Bayer’s share price climbed nearly six percent to 74.06 euros in after-hours trading following the surprise announcement.The Roundup deal would bring closure to around 75 percent of current litigation that involves roughly 125,000 filed and unfiled claims, the statement said.It would also settle about 95 percent of the cases currently set for trial and establish “key values and parameters” to resolve the remainder of the claims, Bayer added. ‘Hard-fought battle’ Roundup is a flagship Monsanto product containing glyphosate, a widely used weedkiller that tens of thousands of plaintiffs say caused their illness — with many suffering from the blood cancer non-Hodgkin’s lymphoma.Bayer suffered a clutch of financially painful setbacks in first-instance US court rulings last year, although the amounts awarded were later reduced.The legal woes have weighed heavily on the group’s share price with many observers and investors questioning the wisdom of the Monsanto takeover.Jennifer Moore, a lawyer representing several Roundup plaintiffs, welcomed the deal.”This settlement is significant for our clients because this has been a long, hard-fought battle and it brings justice for our clients,” she told AFP.Bayer maintains that scientific studies and regulatory approvals show Roundup’s main ingredient glyphosate is safe, but said when it released first-quarter earnings data in April that it “continues to engage constructively in the mediation process”.The settlement announced on Wednesday consists of a payment of $8.8 billion to $9.6 billion to resolve the current Roundup litigation, Bayer said, and $1.25 billion to address potential future litigation.Bayer stressed that the agreement would not cover three cases currently going through the appeals process.They include the landmark first Roundup case brought by school groundskeeper Dewayne Johnson who was eventually awarded $78.5 million. Dicamba deal In the same statement, Bayer said it would pay $820 million to settle decades-old complaints over Monsanto-made toxic chemicals known as PCBs that caused water contamination.It also agreed to settle US lawsuits involving dicamba herbicide which has been blamed for wrecking crops in America, by drifting on to plants unable to resist it.The group said it would pay up to $400 million to resolve pending claims in Missouri for the 2012-2015 crop years. Bayer said it expects co-defendant BASF — which also manufacturers a type of dicamba — to contribute towards the settlement.It comes after a US jury in February awarded $265 million to Missouri peach farmer Bill Bader who accused the two companies of encouraging farmers to use the weedkiller irresponsibly.Bayer said the Bader case was not included in the proposed settlement. “The company believes the verdict in Bader Farms is inconsistent with the evidence and the law and will continue to pursue post-trial motions and an appeal, if necessary,” it said.Bayer said it would make the first cash payments related to the mass settlements starting this year. Part of the funds will come from the sale of its profitable animal health unit.”All three settlements are in the best interest of the company and our stakeholders,” said supervisory board chairman Norbert Winkeljohann. German chemical giant Bayer said on Wednesday it had agreed to pay more than $10 billion to end a wave of lawsuits from Americans who say their cancers were caused by its Roundup weedkiller.The deal relieves a major headache for Bayer, which has been going on since it bought US firm and Roundup maker Monsanto for $63 billion in 2018.”The Roundup settlement is the right action at the right time for Bayer to bring a long period of uncertainty to an end,” said CEO Werner Baumann in a statement.last_img read more

first_imgRED BANK – The Red Bank Volunteer Fire Depart­ment held its annual chiefs election at the Red Bank Borough Courthouse. Members selected Thomas “TD”’ Doremus as chief for 2013, Thomas J. Welsh as first deputy chief and Joseph Lauterwasser as second deputy chief.Doremus is the fifth generation from his family to be a member of the Red Bank Fire Department, following his dad Thomas and his grandfather, Albert, as chief of the department.Red Bank Fire Chief Joshua Sanders (second from the left) congratulates incoming Chief Thomas “TD” Doremus and hands over the chief’s helmet to him as First Deputy Chief Thomas J. Welsh (left) and Second Deputy Chief Joseph Lauterwasser look on.Welsh is on his second, three-year term as a chief serving the Red Bank community. He is also a Red Bank fire marshal. Lauterwasser is a second-generation firefighter. His father George is a former departmental chief.A reception and celebration was held Tuesday, Dec. 4, at Independent Engine Company on Mechanic Street following the election. Mayor Pasquale Menna and Red Bank Fire Commis­sioner Arthur Murphy said a few words and commended the department on the excellent job it did during and after Super Storm Sandy. The borough officials then presented the new chiefs with their badges. Fire department members stop­ped by throughout the evening to congratulate the new chiefs.last_img read more

first_imgARCADIA, Calif. (Nov. 3, 2016)–Beaten 22 ½ lengths in the Grade I Pacific Classic on Aug. 20 and winless in 18 starts since winning the Grade II Charles Town Classic in April, 2014, Imperative rallied boldly from last to take Thursday’s $80,000 Big Bear Stakes by 1 ¼ lengths under Kent Desormeaux, who hadn’t been aboard in a year and a half. Trained by Richard Baltas, Imperative, a 6-year-old Bernardini gelding, got one mile in 1:35.98.“I think he can beat anyone in the world when he wants to,” said Desormeaux, who was also aboard for Imperative’s signature win in the Charles Town Classic. “He’s the kind of horse, he’s either gonna show up or he’s not. So I just (left him alone) until we got to the quarter pole and when I asked him, he just took off.”Owned by J K Racing Stable, Imperative was the 7-5 favorite in a field of eight 3-year-olds and up and paid $4.80, $3.00 and $2.40. In garnering his fourth win from 34 career starts, Imperative picked up a winner’s check of $50,400, which increased his earnings to $2,002,365.“He’s just a horse that’s hard to ride,” said Baltas, who has been the trainer of record for his last nine starts. “There’s a particular way to ride him and Kent knows how to ride him.”Pacesetter Conquest Cobra repelled a stiff challenge from eventual third place finisher Magic Mark, but was no match for the winner and had to settle for second, 3 ¼ lengths clear of “Magic.” Ridden by Rafael Bejarano, Conquest Cobra was off at 7-2 and paid $4.20 and $2.80.Magic Mark, with Drayden Van Dyke aloft, was off at 3-1 and paid $2.80 to show.Fractions on the race were 23.15, 46.75, 1:11.28 and 1:23.54.Friday is day one of the Breeders’ Cup World Championships. Accordingly, Santa Anita admission gates will open at 9 a.m. and first live race post time is at 11:25 a.m.Friday’s main event is the Grade I, $2 million Breeders’ Cup Distaff, which has been carded as the ninth race on a 10-race program. The Distaff will feature what looms an epic showdown between three Eclipse Award winners, the undefeated Songbird, Beholder and Stellar Wind.last_img read more